o NoneEntity Type
0001624326
PAXmed Inc.
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 PAVmed Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 PAVmed Inc. 
Street Address 1Street Address 2
 ONE GRAND CENTRAL PLACE SUITE 4600
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 NEW YORK NEW YORK 10165 212-949-4319 



3. Related Persons
Last NameFirst NameMiddle Name
AklogLishan
Street Address 1Street Address 2
ONE GRAND CENTRAL PLACESUITE 4600
CityState/Province/CountryZIP/Postal Code
NEW YORKNEW YORK10165
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
GlennonMichael
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
CoxJamesL
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SparksRonaldM.
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
Weild, IVDavidScott
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
Battleman, M.D.DavidS.
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
McGrathDennisM.
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
O'NeilShaun
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
YazbeckRichard
Street Address 1Street Address 2
One Grand Central PlaceSuite 4600
CityState/Province/CountryZIP/Postal Code
New YorkNEW YORK10165
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  x Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
x No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
o Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-04-30 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities x Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 Maxim Group LLC 120708
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 405 LEXINGTON AVENUE  
City State/Province/CountryZIP/Postal Code
 NEW YORK NEW YORK 10174
State(s) of Solicitation o All States o Foreign/Non-US
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 4111111 USD o Indefinite
Total Amount Sold $ 4111111 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 120250 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more PAVmed Charts.
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more PAVmed Charts.

Pavmed Inc. News

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Friday 3 May 2024 (2 days ago) • PR Newswire (US)
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Thursday 2 May 2024 (3 days ago) • PR Newswire (US)
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
Thursday 2 May 2024 (3 days ago) • PR Newswire (US)
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Tuesday 30 April 2024 (5 days ago) • PR Newswire (US)
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
Monday 29 April 2024 (6 days ago) • PR Newswire (US)
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Monday 8 April 2024 (4 weeks ago) • PR Newswire (US)
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
Wednesday 27 March 2024 (1 month ago) • PR Newswire (US)
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Friday 22 March 2024 (1 month ago) • PR Newswire (US)
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
Thursday 21 March 2024 (1 month ago) • PR Newswire (US)
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Wednesday 20 March 2024 (2 months ago) • PR Newswire (US)
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
Wednesday 13 March 2024 (2 months ago) • PR Newswire (US)
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
Tuesday 12 March 2024 (2 months ago) • PR Newswire (US)

More Pavmed Inc. News Articles